MedTrace Logo

OssiMend BA in Posterolateral Instrumented Lumbar Fusion

NCT04775537 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2025-10-16

No results posted yet for this study

Summary

The primary objective of this study is to measure the success rate of lumbar fusion in subjects at 12 months when instrumented lumbar arthrodesis is performed using OssiMend Bioactive Moldable as the bone grafting material

Conditions

  • Spinal Disease
  • Degenerative Disc Disease

Interventions

DEVICE

OssiMend™ Bioactive Moldable

Lumbar Spine fusion with OssiMend™ Bioactive Moldable

Sponsors & Collaborators

  • Collagen Matrix

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-21
Primary Completion
2026-12-30
Completion
2027-01-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04775537 on ClinicalTrials.gov